China CAS:1778-02-5 Manufacturers, Suppliers and Factory - Humanwell

China CAS:1778-02-5 Manufacturer

Sticking to the principle of "Super Good quality, Satisfactory service" ,We are striving to become an excellent organization partner of you for CAS:1778-02-5,Pregnenolone, Our goal is always to enable clients comprehend their plans. We have been creating good endeavours to accomplish this win-win scenario and sincerely welcome you to join us.
CAS:1778-02-5, We severely promise that we give all the customers with the best quality products and solutions, the most competitive prices and the most prompt delivery. We hope to win a resplendent future for customers and ourselves.

Hot Products

  • Mifepristone

    Mifepristone

    Mifepristone has specifications of CP and IP. DMF and GMP approved.

    CAS:84371-65-3

  • Drospirenone

    Drospirenone

    Drospirenone has EP,USP specifications. DMF approved.

    CAS:67392-87-4

  • Megestrol Acetate

    Megestrol Acetate

    Megestrol acetate has CP, EP and USP specifications. DMF under filing.

    CAS:595-33-5

  • Valganciclovir Hydrochloride

    Valganciclovir Hydrochloride

    Valganciclovir Hydrochloride has USP specification. DMF approved.

    CAS:175865-59-5

  • 16-Dehydropregnenolone Acetate (16-DPA)

    16-Dehydropregnenolone Acetate (16-DPA)

    16-Dehydropregnenolone Acetate (16-DPA) is the dehydration product of Pregnenolone Acetate..

    CAS:979-02-2

  • Abiraterone

    Abiraterone

    Abiraterone is a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), It is used in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has already spread to other parts of the body) and metastatic high-risk castration-sensitive prostate cancer.

    CAS:154229-19-3

Send Inquiry

  • E-mail
  • QR
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy